A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Trial Details

NCT ID

NCT07023627

Phase

PHASE2

Sponsor

Incyte Corporation

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• INCB123667

Locations (sample)

• Mobile, Alabama, United States|30.69436,-88.04305
• Los Angeles, California, United States|34.05223,-118.24368
• San Diego, California, United States|32.71571,-117.16472
• Washington D.C., District of Columbia, United States|38.89511,-77.03637
• Fort Myers, Florida, United States|26.62168,-81.84059

Key Eligibility Criteria

• Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Have platinum-resistant disease:
• Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen.
• Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.